BD (NYSE:BDX) announced today that it will collaborate with Mayo Clinic Platform to perform detailed post-market surveillance.
Franklin Lakes, New Jersey-based BD’s collaboration with Mayo Clinic Platform will access de-identified patient data from the Mayo Clinic Platform_Discover to perform post-market surveillance on the company’s products and fuel innovation, unlocking a faster, more efficient path to market with the overarching goal of improving patient care.
According to a news release, Mayo Clinic Platform_Discover represents a robust de-identified data set available from 10 million patients, including both structured and unstructured data, images, 1.2 billion lab test results, 3 million echocardiograms and more than 640 million clinical notes.
BD intends to use the platform’s capabilities in data mining, next-generation artificial intelligence (AI) and machine learning tools to analyze real-world data to generate insight into th…